Robert Warmerdam
@robertwarmerdam.bsky.social
🧬 New preprint alert! After years of collaborative work across 52 datasets we are presenting eQTLGen phase 2: a genome-wide eQTL meta-analysis covering 43,301 blood samples: www.medrxiv.org/content/10.6... (1/8)
February 6, 2026 at 10:14 AM
🧬 New preprint alert! After years of collaborative work across 52 datasets we are presenting eQTLGen phase 2: a genome-wide eQTL meta-analysis covering 43,301 blood samples: www.medrxiv.org/content/10.6... (1/8)
Reposted by Robert Warmerdam
Just out! Our manuscript (led by Pauline Lanting and @robertwarmerdam.bsky.social) on the generation of pharmacogenetic passports from low-cost GSA oligonucleotide array data.
📣New from Lanting et al.
📄Low-cost generation of clinical-grade, layperson-friendly pharmacogenetic passports using oligonucleotide arrays
#PGx
📄Low-cost generation of clinical-grade, layperson-friendly pharmacogenetic passports using oligonucleotide arrays
#PGx
Low-cost generation of clinical-grade, layperson-friendly pharmacogenetic passports using oligonucleotide arrays
Almost all individuals will carry a genetic marker that affects their drug response
and warrants therapy adjustments. This study demonstrates the feasibility of a low-cost,
pre-emptive pharmacogenetic...
www.cell.com
April 4, 2025 at 10:08 AM
Just out! Our manuscript (led by Pauline Lanting and @robertwarmerdam.bsky.social) on the generation of pharmacogenetic passports from low-cost GSA oligonucleotide array data.